Current Report Filing (8-k)
August 07 2018 - 4:16PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
Current
Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): August 2, 2018
Corcept Therapeutics Incorporated
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-50679
|
|
77-0487658
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification Number)
|
149 Commonwealth Drive
Menlo Park, CA 94025
(Address of principal executive offices, with zip code)
(650)
327-3270
(Registrants telephone number, including area code)
Not Applicable
(Former
name or former, address, if changed since last report)
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR 240.14d2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR 240.13e4(c))
|
Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule
12b-2
of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
Item 7.01 Regulation FD Disclosure
On August 2, 2018, Neptune Generics, LLC submitted a petition for Inter Partes Review (IPR) at the U.S. Patent Trial and Appeal Board (PTAB) of U.S.
Patent No. 8,921,348 (348) which is related to Corcepts Korlym
®
product.
Neptune Generics, LLC does not have regulatory approval to sell any drug in the United States. It is backed by the litigation finance firm, Burford Capital
Ltd., a U.K.-based company. The PTAB has not accorded a filing date to this petition.
Corcept plans to vigorously defend the validity of the 348
patent.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
CORCEPT THERAPEUTICS INCORPORATED
|
|
|
By:
|
|
/s/ G. Charles Robb
|
|
|
Name:
|
|
G. Charles Robb
|
|
|
Title:
|
|
Chief Financial Officer and Secretary
|
Date: August 7, 2018
Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Corcept Therapeutics (NASDAQ:CORT)
Historical Stock Chart
From Apr 2023 to Apr 2024